In pediatric oncology, for example, dysregulation of the RISC pathway can contribute to the development and progression of cancers such as neuroblastoma and Wilms' tumor. Studies have shown that specific miRNAs, when aberrantly expressed, can act as oncogenes or tumor suppressors. Understanding the role of RISC in these contexts can help in developing targeted therapies that aim to correct these molecular abnormalities.
